About: serous carcinoma

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: serous carcinoma Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

Attributes	Values
rdf:type	Item
owl:sameAs	serous carcinoma
description	Krankheit (de) malattia (it) хвороба (uk)
rdfs:label	serous carcinoma (en) 漿液性癌 (zh-hant) 黏液細胞癌 (zh) carcinome séreux (fr) serozni karcinom (sl) 浆液性癌 (zh-cn)
skos:prefLabel	serous carcinoma (en) 漿液性癌 (zh-hant) 黏液細胞癌 (zh) carcinome séreux (fr) serozni karcinom (sl) 浆液性癌 (zh-cn)
name	serous carcinoma (en) 漿液性癌 (zh-hant) 黏液細胞癌 (zh) carcinome séreux (fr) serozni karcinom (sl) 浆液性癌 (zh-cn)
instance of	wds:Q7455058-4B4272A8-6EC3-4B4D-A0CA-ABEBAFB25E38
instance of	disease
subclass of	wds:Q7455058-74e4d0ab-4c4d-ddbf-5a1c-7fbe8a9b90f1 wds:Q7455058-a745ad13-499a-ecc2-a35a-44c883470de9
subclass of	carcinoma Serous tumour
UMLS CUI	wds:Q7455058-dbee4255-4be9-99bd-edd7-8a9bafe285e9
UMLS CUI	C0476127
is about of	serous carcinoma https://www.wikidata.org/wiki/Special:EntityData/Q7455058 Serous carcinoma
is subclass of of	low-grade serous carcinoma high-grade serous carcinoma serous cystadenocarcinoma ovarian serous carcinoma
is subclass of of	wds:Q123750979-fd5db6c9-4cbd-2e5d-a694-6033de9e29bf wds:Q28134897-f740d444-4dcd-c4ce-cdc4-70f8e9450392 wds:Q7455060-61ca6568-42c6-6c6b-9179-d71ec1a30f5e wds:Q18553575-15949a43-4dec-1ed9-79bd-65411d38563d
is main subject of	Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study Low-grade ovarian serous neoplasms (low-grade serous carcinoma and serous borderline tumor) associated with high-grade serous carcinoma or undifferentiated carcinoma: report of a series of cases of an unusual phenomenon. Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy Is adjuvant therapy necessary for stage IA and IB uterine papillary serous carcinoma and clear cell carcinoma after surgical staging? Personal history of breast cancer as a significant risk factor for endometrial serous carcinoma in women aged 55 years old or younger. Prognostic determinants in patients with stage IIIC and IV uterine papillary serous carcinoma Endometrial Glandular Dysplasia with Frequent p53 Gene Mutation: A Genetic Evidence Supporting Its Precancer Nature for Endometrial Serous Carcinoma Somatic D-loop mitochondrial DNA mutations are frequent in uterine serous carcinoma WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma Programmed cell death 4 and microRNA 21 inverse expression is maintained in cells and exosomes from ovarian serous carcinoma effusions The role of optimal debulking in advanced stage serous carcinoma of the uterus Increased androgen receptor expression in serous carcinoma of the ovary is associated with an improved survival EGF-induced EMT and invasiveness in serous borderline ovarian tumor cells: a possible step in the transition to low-grade serous carcinoma cells? Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study Critical molecular abnormalities in high-grade serous carcinoma of the ovary The biologic behavior of low-grade papillary serous carcinoma of the ovary A limited panel of immunomarkers can reliably distinguish between clear cell and high-grade serous carcinoma of the ovary Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary Comparison of clinical outcomes of patients with clear cell and endometrioid ovarian cancer associated with endometriosis to papillary serous carcinoma of the ovary Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from breast carcinoma in effusions Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses. Genetic alterations of the WT1 gene in papillary serous carcinoma of the peritoneum Comparison of outcomes in early stage uterine carcinosarcoma and uterine serous carcinoma Brain metastasis in two patients with stage IA papillary serous carcinoma of the uterus Minimal uterine serous carcinoma: a clinicopathological study of 40 cases Serous EIC as an early form of uterine papillary serous carcinoma: recent progress in understanding its pathogenesis and current opinions regarding pathologic and clinical management Molecular identification of "latent precancers" for endometrial serous carcinoma in benign-appearing endometrium Early stage uterine serous carcinoma: management updates and genomic advances Serous carcinoma of the ovary and peritoneum with metastases to the breast and axillary lymph nodes: a potential pitfall A BRCA1/2 Mutational Signature and Survival in Ovarian High-Grade Serous Carcinoma Her2/neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumab The cadherin switch in ovarian high-grade serous carcinoma is associated with disease progression beta-catenin nuclear localization is associated with grade in ovarian serous carcinoma Uterine papillary serous carcinoma: a review KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma Intercepting early pelvic serous carcinoma by routine pathological examination of the fimbria Development of targeted therapy in uterine serous carcinoma, a biologically aggressive variant of endometrial cancer Dual HER2 targeting impedes growth of HER2 gene-amplified uterine serous carcinoma xenografts Inhibition of gamma-secretase activity impedes uterine serous carcinoma growth in a human xenograft model HER2/neu gene amplification determines the sensitivity of uterine serous carcinoma cell lines to AZD8055, a novel dual mTORC1/2 inhibitor. Oncogenic PIK3CA gene mutations and HER2/neu gene amplifications determine the sensitivity of uterine serous carcinoma cell lines to GDC-0980, a selective inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2). Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice The oncofetal protein IMP3: a novel biomarker for endometrial serous carcinoma A genetically engineered ovarian cancer mouse model based on fallopian tube transformation mimics human high-grade serous carcinoma development. "Primary peritoneal" high-grade serous carcinoma is very likely metastatic from serous tubal intraepithelial carcinoma: assessing the new paradigm of ovarian and pelvic serous carcinogenesis and its implications for screening for ovarian cancer Noninvasive and invasive micropapillary (low-grade) serous carcinoma of the ovary: a clinicopathologic analysis of 135 cases. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship. Chromosomal instability in fallopian tube precursor lesions of serous carcinoma and frequent monoclonality of synchronous ovarian and fallopian tube mucosal serous carcinoma Mixed ovarian epithelial carcinomas with clear cell and serous components are variants of high-grade serous carcinoma: an interobserver correlative and immunohistochemical study of 32 cases Clear cell carcinoma compared to serous carcinoma in early ovarian cancer: same prognosis in a large randomized trial Uterine papillary serous carcinoma: a study on 108 cases with emphasis on the prognostic significance of associated endometrioid carcinoma, absence of invasion, and concomitant ovarian carcinoma Markers of proliferative activity are predictors of patient outcome for low-grade endometrioid adenocarcinoma but not papillary serous carcinoma of endometrium Uterine papillary serous carcinoma: what have we learned over the past quarter century? Her-2/neu overexpression and amplification in uterine papillary serous carcinoma

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 193 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software